GENinCode plc Logo

GENinCode plc

GENI.L

(1.0)
Stock Price

4,15 GBp

-179.94% ROA

-286.76% ROE

-0.72x PER

Market Cap.

9.290.610,00 GBp

23.2% DER

0% Yield

-324.81% NPM

GENinCode plc Stock Analysis

GENinCode plc Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

GENinCode plc Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.88x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a minimal amount of debt (4%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 ROE

The stock's ROE indicates a negative return (-51.43%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-48.4%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

6 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

7 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

GENinCode plc Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

GENinCode plc Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Sell
4 Stoch RSI Buy

GENinCode plc Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

GENinCode plc Revenue
Year Revenue Growth
2019 1.921.989
2020 960.801 -100.04%
2021 1.154.000 16.74%
2022 1.430.000 19.3%
2023 2.420.000 40.91%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

GENinCode plc Research and Development Expenses
Year Research and Development Expenses Growth
2019 0
2020 0 0%
2021 1.000 100%
2022 72.000 98.61%
2023 668.000 89.22%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

GENinCode plc General and Administrative Expenses
Year General and Administrative Expenses Growth
2019 204.843
2020 1.573.020 86.98%
2021 2.006.000 21.58%
2022 6.266.000 67.99%
2023 7.830.000 19.97%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

GENinCode plc EBITDA
Year EBITDA Growth
2019 -476.260
2020 -1.035.363 54%
2021 -2.887.000 64.14%
2022 -5.569.000 48.16%
2023 -6.928.000 19.62%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

GENinCode plc Gross Profit
Year Gross Profit Growth
2019 1.039.758
2020 523.016 -98.8%
2021 593.000 11.8%
2022 632.000 6.17%
2023 1.110.000 43.06%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

GENinCode plc Net Profit
Year Net Profit Growth
2019 -403.725
2020 -1.066.640 62.15%
2021 -4.142.000 74.25%
2022 -5.559.000 25.49%
2023 -7.030.000 20.92%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

GENinCode plc Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2019 -6
2020 -9 33.33%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

GENinCode plc Free Cashflow
Year Free Cashflow Growth
2019 -314.377
2020 -1.106.054 71.58%
2021 -3.169.000 65.1%
2022 -4.611.000 31.27%
2023 -1.518.000 -203.75%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

GENinCode plc Operating Cashflow
Year Operating Cashflow Growth
2019 -190.703
2020 -1.037.781 81.62%
2021 -3.024.000 65.68%
2022 -3.762.000 19.62%
2023 -1.518.000 -147.83%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

GENinCode plc Capital Expenditure
Year Capital Expenditure Growth
2019 123.674
2020 68.273 -81.15%
2021 145.000 52.92%
2022 849.000 82.92%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

GENinCode plc Equity
Year Equity Growth
2019 -440.009
2020 1.858.746 123.67%
2021 13.718.000 86.45%
2022 7.900.000 -73.65%
2023 1.289.000 -512.88%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

GENinCode plc Assets
Year Assets Growth
2019 489.089
2020 2.422.241 79.81%
2021 15.210.000 84.07%
2022 11.797.000 -28.93%
2023 4.186.000 -181.82%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

GENinCode plc Liabilities
Year Liabilities Growth
2019 929.098
2020 563.495 -64.88%
2021 1.492.000 62.23%
2022 3.897.000 61.71%
2023 2.897.000 -34.52%

GENinCode plc Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.02
Net Income per Share
-0.07
Price to Earning Ratio
-0.72x
Price To Sales Ratio
4.3x
POCF Ratio
-0.67
PFCF Ratio
-1.23
Price to Book Ratio
3.9
EV to Sales
3.29
EV Over EBITDA
-1.03
EV to Operating CashFlow
-0.95
EV to FreeCashFlow
-0.94
Earnings Yield
-1.39
FreeCashFlow Yield
-0.81
Market Cap
0,01 Bil.
Enterprise Value
0,01 Bil.
Graham Number
0.15
Graham NetNet
0

Income Statement Metrics

Net Income per Share
-0.07
Income Quality
1.07
ROE
-2.87
Return On Assets
-1.68
Return On Capital Employed
-4.17
Net Income per EBT
1
EBT Per Ebit
0.98
Ebit per Revenue
-3.31
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
2.7
Research & Developement to Revenue
0.15
Stock Based Compensation to Revenue
0.02
Gross Profit Margin
0.39
Operating Profit Margin
-3.31
Pretax Profit Margin
-3.25
Net Profit Margin
-3.25

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.08
Free CashFlow per Share
-0.08
Capex to Operating CashFlow
-0.01
Capex to Revenue
0.02
Capex to Depreciation
0.11
Return on Invested Capital
-4.5
Return on Tangible Assets
-1.8
Days Sales Outstanding
86.01
Days Payables Outstanding
332.17
Days of Inventory on Hand
23.37
Receivables Turnover
4.24
Payables Turnover
1.1
Inventory Turnover
15.62
Capex per Share
0

Balance Sheet

Cash per Share
0,03
Book Value per Share
0,01
Tangible Book Value per Share
0.01
Shareholders Equity per Share
0.01
Interest Debt per Share
0
Debt to Equity
0.23
Debt to Assets
0.07
Net Debt to EBITDA
0.32
Current Ratio
1.29
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
1713000
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.07
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
84000
Debt to Market Cap
0.03

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

GENinCode plc Dividends
Year Dividends Growth

GENinCode plc Profile

About GENinCode plc

GENinCode Plc engages in the development and commercialization of clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally. Its predictive technology provides patients and physicians with preventative care and treatment strategies. The company's molecular tests combine clinical algorithms and artificial intelligence to provide advanced patient risk assessment to predict disease onset. Its tests include Cardio inCode, a patented genetic test to help user to adopt cardiovascular prevention steps; Lipid inCode, a genetic diagnostic test, which analyzes the seven genes associated with familial hypercholesterolemia; SUDD inCode, a genetic test to diagnose the cause of sudden cardiac death and familial heart disease; Thrombo inCode, a genetic test that analyzes 12 genetic variants related to hereditary thrombophilia and the risk of thrombosis; and Thrombo inCode Reproductive Health, a genetic test that offers information related to risk of thrombophilia and associated risks for future pregnancies. GENinCode Plc was incorporated in 2018 and is based in Oxford, the United Kingdom.

CEO
Mr. Matthew Heaton Walls
Employee
42
Address
Oxford Science Park
Oxford, OX4 4GP

GENinCode plc Executives & BODs

GENinCode plc Executives & BODs
# Name Age
1 Mr. Jordi Puig Gilberte
Co-Founder, Chief Operating Officer & Director
70
2 Mr. Paul Andrew Peter Foulger
Chief Financial Officer, Company Secretary & Director
70
3 Mr. Matthew Heaton Walls
Co-Founder, Chief Executive Officer & Director
70

GENinCode plc Competitors

Belluscura plc Logo
Belluscura plc

BELL.L

(0.8)
Poolbeg Pharma PLC Logo
Poolbeg Pharma PLC

POLB.L

(1.0)
Trellus Health plc Logo
Trellus Health plc

TRLS.L

(1.0)
Destiny Pharma plc Logo
Destiny Pharma plc

DEST.L

(0.8)
ANGLE plc Logo
ANGLE plc

AGL.L

(1.0)